May 7, 2010

Genovis: Premiere for unique product concept

Regulatory

Genovis is presenting new results that can facilitate and improve production and quality control of substances such as antibody-based drugs. The results are based on a study carried out in cooperation with Lund University. The study shows that the combination of two unique products from Genovis’ protein engineering portfolio is highly advantageous in mass spectroscopy of antibody molecules. The faster, more reliable new method improves the analysis compared with existing technology. The results are being presented at the international conference Immunology 2010 held May 7 – 10 in Baltimore, USA.

“With this new concept we can offer producers of antibodies and antibody-based drugs new tools for improved and more cost-effective quality control. We will launch the concept immediately. It is important for Genovis to broaden the customer base for our products and the excellent results from this study provide an excellent opportunity to attract new customers,” says Sarah Fredriksson, CEO of Genovis.

Mass spectroscopy (MS) is an analytical technique to determine the chemical composition in substances such as proteins and peptides.

Meet Sarah Fredriksson May 8-10 in booth number 113, Bulldog Bio.
Follow Genovis on Facebook and Twitter

Genovis protein portfolio
Genovis produce and market three different proteins with trade names FabRICATOR®, IgGZERO™ and FcDOCKER™. FabRICATOR is recombinant IdeS, a cysteine protease which cleaves the IgG molecule in the hinge region (Popular science animation of FabRICATOR see http://www.youtube.com/user/biotechgenovis ). IgGZERO is recombinant EndoS, an endoglycosidase which hydrolyze glycans attached to the Fc-fragments of IgG molecules. FcDOCKER is a mutated form of EndoS that can be used for affinity purification of IgG molecules.

wkr0011.pdf